| HOME >> BIOLOGY >> TECHNOLOGY |
- Lead Clinical Program and Two Clinical Candidates Featured -
SOUTH SAN FRANCISCO, Calif., Feb. 12 /PRNewswire/ -- Raven biotechnologies, inc., a privately held company focused on the discovery and development of monoclonal antibody therapeutics (MAbs) for cancer, announced four abstracts have been selected for presentation at the meeting of American Association for Cancer Research being held in San Diego on April 12-16, 2008.
"We are pleased to have this opportunity to present important data on
both RAV12, Raven's lead therapeutic antibody entering Phase 2 development
for the treatment of adenocarcinomas and the promising near-term clinical
candidates in our oncology pipeline," stated George Schreiner, M.D., Ph.D.,
chief executive officer of Raven biotechnologies. "Raven will present
significant new data on RAV12 supporting the chemotherapeutic synergies
that inform its impending phase 2 trials. In addition, recent discoveries
concerning novel epitopes and effector mechanisms associated with two new
antibodies targeting cancer stem cells will be presented for the first
time. Both antibodies are slated for clinical development. Finally, having
advanced the technology to culture cancer stem cells on a sustained basis
in vitro, we will present their in vivo biology, using prostate cancer stem
cells as an important new model system for understanding the growth and
metastasis of human cancer."
The presentations are scheduled as follows:
Oral Presentation in a Minisymposium Session
The anti-B7-H3-4Ig antibody TES7 recognizes cancer stem cell lines,
modulates angiogenic factor secretion, and exhibits potent anti-tumor
activity in vivo
Session ID: Experimental and Molecular Therapeutics 24
Date and Time: Monday, April 14, 2008, 1:00 PM
Abstract Number: 2555
Poster Sessions
Human prostate cancer stem cell line spontaneously metastasizes in vivo
Session ID: Tumor
'/>"/>
| SOURCE Raven biotechnologies, inc. Copyright©2008 PR Newswire. All rights reserved |